Trial Profile
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs Pidilizumab (Primary) ; Dendritic cell vaccines
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 09 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 25 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.
- 01 Aug 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Dec 2021.